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ABSTRACT
Glioblastoma multiforme is the most aggressive and common primary brain 
tumor, and is virtually incurable due to its therapeutic resistance to radiation and 
chemotherapy. Curcumin is a well-known phytochemical exhibiting antitumor activity 
on many human cancers including glioblastoma multiforme. Given the unique miRNA 
expression profiles in cancer cells compared to non-cancerous cells, we investigated 
whether these miRNA could be used to cancer therapy. In this report we show that 
miR-378, a glioblastoma multiforme down regulated miRNA, may enhance the inhibitory 
effect of curcumin on this cancer growth. Our results indicated that the inhibitory effect 
of curcumin was enhanced in miR-378-expressing stable U87 cells in vitro and in vivo, 
compared to control cells. MiR-378 was found to target p-p38 expression, underlying 
the observed phenotypic changes. Thus, we concluded that miR-378 enhances the 
response of glioblastoma multiforme to curcumin treatment, by targeting p38.
INTRODUCTION
Glioblastoma multiforme (GBM) is the most common 
and most aggressive malignant brain tumor that accounts 
for 40% of all brain tumors, with only a about 3% five-year 
survival rate [1]. It is difficult to treat surgically, or with 
chemotherapy or radiotherapy, given its highly proliferative 
and invasive nature [2]. Little progress has been achieved 
in the treatment of GBM over the last twenty years, partly 
due to a poor mechanistic understanding of GBM, and thus 
a lack of effective therapeutic targets [3].
MicroRNAs (miRNAs) are small non-coding RNA 
molecules containing about 22 nucleotides that regulate 
gene expression at the post-transcriptional level. Some of 
the miRNAs are expressed specifically in the mammalian 
brain and retina, indicating that this group of miRNAs 
might be involved in the development of neural tissues [4, 
5]. Moreover, since unique microRNA expression profiles 
have been frequently identified in various cancer cells, 
such as lung cancer [6] and cervical cancer [7]. Abnormal 
expression of miR-378 has been reported in many cancer 
cell lines, such as K562, Jurkat, and HL-60 [8]. It was 
also found that miR-378 expression was suppressed 
in GBM [9]. It has been found miRNAs may influence 
drug resistance in cancer treatment [10, 11]; hence more 
and more studies have been launched to investigate the 
synergistic effects of miRNAs and approved drugs in 
cancer treatment.
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Curcumin is a natural polyphenol compound that 
has been widely used in the inflammation, respiratory 
diseases, and cancer therapeutics [12, 13]. It had been 
reported that curcumin possesses anticancer effects by 
regulating functions of numerous targets such as nuclear 
factor NF-κB, extracellular signal-regulated kinase 
(ERK), and cell cycle proteins [14, 15]. It has also been 
demonstrated that curcumin might inhibit multiple matrix-
metalloproteinases, suppressing GBM proliferation, and 
inducing apoptosis or autophagy [16, 17].
In this study we examined whether miR-378 may 
influence the effect of curcumin on GBM and we found 
that miR-378 enhanced the response of Glioblastoma cells 
to curcumin treatment.
RESULTS
miR-378 potentiates inhibitory effect of 
curcumin on GBM growth
The effects of curcumin on SCID mice xenograft tumor 
model were first examined. Both U87-miR-378 and control 
U87-GFP cells formed obvious tumors at Day 11 post-injection 
(Figure 1A & 1B). Mouse body weight was not affected by 
drug treatment (Figure 1E & 1F). According to the results, 
the growth of U87-miR-378 tumors (Figure 1A & 1C) was 
significantly inhibited by 60 mg/kg curcumin (611.2 ± 214.6, 
P<0.01) and 120 mg/kg curcumin (358.8 ± 166.5, P<0.01) 
when compared with the PVP (Polyvinylpyrrolidione) group 
(881.32 ± 189.84) after 2 weeks of treatment. There was no 
significant difference between the PVP group and PBS groups 
(1046.5± 221.9, P>0.05). There was also no statistically 
significant difference in the 60 mg/kg group (494.4 ± 283.1, 
P>0.05) or 120 mg/kg group (514.5 ± 138.3, P>0.05) when 
compared with PVP group (697.4 ± 228.8) (Figure 1B & 1D). 
Our in vivo study indicated that 60 mg/kg and 120 mg/kg 
curcumin was sufficient to suppress tumor growth induced 
by miR-378 expression.
To investigate the mechanism underlying the 
interaction between miR-378 and curcumin, western blot was 
performed to determine the expression of phosphorylation 
extracellular signal-regulated kinase (ERK), Akt and P38, 
as well as neuropilin in mice (Figure 1G). We found that 
p-p38 was up-regulated in U87-miR-378 cells formed tumor 
compared to that of U87-GFP cells.
miR-378 enhances the effect of curcumin by 
suppressing cell proliferation and inducing 
apoptosis.
U87 cells over expressing miR-378 were used to 
investigate whether miR-378 could influence the inhibitory 
effect of curcumin on cell proliferation. Stable U87-GFP 
and U87-miR-378 cells were treated with 0 μM, 5 μM, 
15 μM, 25 μM and 50 μM curcumin-PVP. The effects of 
curcumin treatment on cell proliferation in U87-GFP cells 
were consistent with our previous report (Figure 2A). 
Interestingly, we found that 50 μM curcumin demonstrated 
higher inhibition on U87-miR-378 proliferation than on U87-
GFP (P<0.05) after 48 h and 72 h treatments (Figure 2B).
Moreover, 72-hour treatment with 50 μM curcumin 
caused more cell apoptosis in U87-miR-378 compared with 
that in 23.9% vs. 12.8% (Figure 2C). The results suggested 
that the inhibitory effect of miR-378/curcumin observed in 
MTT assay (Figure 2A & 2B) was due to apoptosis but not 
other factors, such as change of cell cycle duration.
To examine whether U87-miR-378 and U87-GFP 
cells behaved differently in forming colonies under 
curcumin treatment, the cells were grown in medium 
supplemented with 0 µM, 5 µM, 10 µM, 15 µM, 25 µM 
curcumin, and colony formation assay was performed. 
This was designed to test whether U87-miR-378 cell were 
less aggressive than U87-GFP cells. Results indicated that 
more colonies were formed by U87-GFP cells compared to 
U87-miR-378 cells, following 15 µM or 25 µM curcumin 
treatment (Figure 2D). Furthermore, the survival rate was 
not significantly different between the two cells at 5 µM 
and 10 µM curcumin treatment, but was significantly 
different at 15 µM (P<0.01, U87-miR-378 VS U87-GFP) 
(Figure 2E) and 25 µM (P<0.01, U87-miR-378 VS U87-
GFP, data not show here). All of the results indicated that 
the U87-miR-378 cell line was more sensitive to 15 µM 
and 25 µM curcumin treatment than U87-GFP.
To confirm our results, we used a loss-of-function 
approach. A miR-378 inhibitor was transfected into 
the cells to confirm the functions of miR-378 described 
above. MTT and apoptosis assays showed that miR-378 
enhanced the sensitivity of curcumin treatment in U87 
cells (Figure 3).
miR-378 enhances U87 cell line responses 
to curcumin treatment via stimulating P38 
signaling pathway
Since miR-378 was reported to be able to regulate 
Mitogen-Activated Protein Kinase Pathway (MAPK) 
[18], we next examined whether the MAPK pathway 
had been affected by the miR-378/curcumin axis. It was 
been found that curcumin suppressed the protein levels 
of phosphorylated p38 in U87 cells (Figure 4A). miR-
378 could counteract the inhibition of p38 by increasing 
phosphorylation of p38, thereby increasing the sensitivity 
of cells to curcumin. There was not significant affection in 
miR-378 level after treated by p38 inhibitor (SB203580) 
(Figure 4B & 4C). The phosphorylation of p38 led to high 
expression of Bax, indicating the increase of apoptosis. 
The insertion of Bax into the mitochondrial membrane 
induces the release of cytochrome C and the induction 
of apoptotic cell death. Furthermore, low expression of 
PCNA was detected after curcumin treatment, indicated 
reduced cell proliferation in U87 cells. PCNA expression 
may be used as a marker of cell proliferation. Collectively, 
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Figure 1: MiR-378 potentiates inhibitory effect of curcumin on GBM growth. (A-F): Curcumin-PVP (Polyvinylpyrrolidione) 
was diluted into 120 mg/kg, 60 mg/kg and 30 mg/kg, and PVP concentration equal to that in 120 mg/kg curcumin-PVP. Source tumors 
were initiated from in vitro cultured cells (U87-miR-378 and U87-GFP cells). Experimental tumors were initiated by subcutaneous chunk 
transfer of source tumors to the hind leg of 6-7 weeks old male SCID mice provided by the Cox-7 defined flora animal facility in MGH. 
After 7 days post implantation, all of the SCID mice were randomly grouped into Control (only PBS), PVP, 30 mg/kg, 60 mg/kg and 120 
mg/kg groups. Each group accepted daily gavage (1 time/mouse/day) for 2 weeks, and the tumors were harvested after last 24h treatment. 
Data are mean± SD (n=3), **p<0.01, the results were repeated in three independent experiments. (G): Western blot analysis of p-P38, 
p-AKT, p-ERK and Neuropolin expressed in U87-miR-378 and U87-GFP tumors. β-actin was used as loading control.
Figure 2: MiR-378 enhances the effect of curcumin by suppressing cell proliferation and inducing apoptosis. (A-B): 
Effects of different concentration curcumin on the growth of U87-GFP and U87-miR-378 cells by MTT assay. U87-GFP and U87-miR-378 
cells were treated with 0 μM, 5 μM, 15 μM, 25 μM and 50 μM curcumin respectively, the tested cells were seeded at density 2000 cells/
well and measured in 24 h, 48 h and 72 h after culture. The experiments were repeated three times and the negative control was conducted 
using only cell-free culture medium (means ± SD). Data are mean± SD (n=3), **p<0.01, the results were repeated in three independent 
experiments. C: Effects of different concentration curcumin on the cell apoptosis of U87-GFP and U87-miR-378 cells by Flow assay. (D-
E): Effects of different concentration curcumin on U87-GFP and U87-miR-378 cells by colony formation assay. The surviving fraction was 
calculated as a ratio of the number of colonies formed and the product of the number of cells plated and the plating efficiency. The results 
were repeated in three independent experiments.
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these data suggested that miR-378 enhanced U87 cell line 
responses to curcumin treatment via stimulating the P38 
signaling pathway.
DISCUSSION
GBM is one of the most common tumors with a 
relatively low survival rate. Due to its highly proliferative 
and invasive nature, finding agents to increase the 
therapeutic efficiency of established drugs is a feasible 
therapeutic strategy. miRNAs, as a novel biomarker, 
have been widely used to predict prognosis and treatment 
efficiency. Nearly 1900 human miRNAs have been 
identified, which can regulate 60~80% of the genes in 
humans [19]. miR-34a, miR-137, and miR124 have been 
reported to play roles in the maintenance of cancer stem 
cell properties [20, 21]. miR-21 and miR-196 has been 
shown to be over-expressed in glioblastoma cell lines and 
glioblastoma patients [22, 23]. miR-138 inhibits GBM cell 
proliferation in vitro and tumorigenicity in vivo through 
inducing cell cycles G1/S arrest [24]. These studies shed 
light on the possibility of targeting miRNA as a direction 
for gene therapy.
Curcumin is a polyphenolic agent with anti-
inflammatory and anticarcinogenic properties, which is 
known to induce apoptotic activity against a variety of 
cancers, such as stomach cancer, colon cancer, breast 
cancer and prostate cancer [25–27]. It can also inhibit 
multiple matrix-metalloproteinase and suppress the growth 
of GBM cell in a dose-and time-dependent manner [28]. 
Our study mainly focuses on whether miR-378 could 
enhance U87 cell line response to curcumin therapy. We 
found that miR-378 significantly enhanced the effect of 50 
µM curcumin treatment by suppressing the proliferation of 
U87 cells (Figure 2). In addition, colony formation assay 
was performed following curcumin treatment in U87-GFP 
Figure 3: MiR-378 enhanced the sensitivity of curcumin treatment in U87 cells. Effects of miR-378 inhibitor, curcumin and 
miR-378 inhibitor on the growth of U87-GFP and U87-miR-378 cells by MTT assay (A) and flow cytometer (B, C). There is significantly 
difference between U87-GFP and U87-miR-378 cells in the curcumin group and miR-378 inhibitor with curcumin group. The t-test was 
used for statistical analysis. Data are mean± SD (n=3), **p<0.01, the results were repeated in three independent experiments. Control In: 
negative miRNA-378 inhibitor; miRNA-378 In: miRNA-378 inhibitor; C: curcumin.
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Figure 4: MiR-378 enhanced the sensitivity of curcumin treatment in U87 cells by p38 signaling pathway. (A): Western 
blot analysis of p-P38, Bax, PCNA expressed in U87-miR-378 and U87-GFP cells with or without curcumin and miR-378 inhibitor treated. 
Con In: control miRNA-378 inhibitor; In: miRNA-378 inhibitor; Cur:curcumin. β-actin was used as loading control. The t-test was used for 
statistical analysis. Data are mean± SD (n=3), the results were repeated in three independent experiments. *p<0.05, **p<0.01 (vs U87-GFP 
control miRNA-378 inhibitor); #p<0.05, ##p<0.01 (vs U87-miRNA-378 control miRNA-378 inhibitor). (B): Western blot analysis of p-P38 
expressed in U87-miR-378 and U87-GFP cells with or without SB203580 (P38 inhibitor) treated. β-actin was used as loading control. The 
t-test was used for statistical analysis. Data are mean± SD (n=3), the results were repeated in three independent experiments. **p<0.01 (vs 
U87-GFP control), ##p<0.01 (vs U87-miR-378 control). (C): qRT-PCR analysis of miRNA-378 levels in U87-miR-378 and U87-GFP cells 
with or without SB203580 (P38 inhibitor) treated. The t-test was used for statistical analysis. Data are mean± SD (n=3), the results were 
repeated in three independent experiments.
Oncotarget73943www.impactjournals.com/oncotarget
and U87-miR-378 cells (Figure 2). The result showed that 
the survival fraction was significantly different in 15 µM 
dose and 25 µM doses (U87-GFP vs U87-miR-378 cell), 
which indicated that the U87-miR-378 cell was more 
sensitive to curcumin treatment. Consistent results were 
also obtained in in vivo xenograft tumor model (Figure 1). 
60 mg/kg and 120 mg/kg curcumin could suppress tumor 
growth formed by U87-miR-378 cells to a greater extent 
compared with control U87-GFP cells.
The mechanism of miR-378 enhanced curcumins 
effects in U87 cells was also investigated by western blot 
(Figures 1 and  4). Our data revealed that miR-378 acquired 
tumor inhibition with curcumin through targeting p-p38. 
Thus, we infer that the reduction in the growth of U87 may 
be caused by decreases phosphorylation of p38, which was 
curbed by miR-378.
p38 activity contributes to the highly invasive 
capacity of GBM cell lines and regulates the expression 
of MMPs, inflammation, and other cell process, making 
it a suitable drug target [29, 30]. A number of studies 
have demonstrated that the p38 MAPK signaling 
pathway is involved in apoptosis in many cell types 
[31–33]. According to the results shown in Figure 4, 
the phosphorylation of p38 leads to increased Bax 
expression, and GBM cell apoptosis. These results are 
consistent with previous reports [34]. Furthermore, we 
found the decrease of PCNA after curcumin treatment, 
which might suggest the inhibition of cell proliferation 
in U87.
MiR-378 has emerged as molecular regulators that 
play key roles in pathogenesis and progression of different 
maliganceise. miR-378a-3p could suppresses activation of 
hepatic stellate cells by targeting Gli3 and its expression 
is regulated by Smo-dependent NF-ΚB signaling, 
suggesting miR-378a-3p has therapeutic potential for 
liver fibrosis [35]. MiR-378 could directly target secreted 
clusterin and help disable the chemoresistance against 
cisplantin in lung adenocarcinoma cells [36]. Besides, 
miR-378 also involved in breast cancer, Browne G et al 
identifies a novel and clinically relevant mechanism for 
regulation of Runx1 in breast cancer that is mediated by 
PPARGC1B-miR-378-Runx1 regulatory pathway [37]. 
overexpression of miR-378 suppressed prostate cancer 
cell migration and invasion promoted cell apoptosis 
and stably miR-378-overexpressed prostate cancer cells 
displayed a significantly reduction in tumor growth 
[38]. Over-expression of miR-378 inhibits glioma cell 
migration and invasion [9]. In addition, the expression 
level miR-378 was significantly lower in glioma tissues 
compared with non-neoplastic brain tissues. Patients with 
lower miR-378 expression levels also have a significantly 
poorer overall survival [39]. Li et al demonstrated that 
miR-378 functioned as a tumor suppressor and played an 
important role in inhibiting tumor migration and invasion 
[9]. All those findings are consistent with the results of 
our work and strongly support that fact that miR-378 may 
synergistically act with curcumin in inhibiting the growth 
of glioblastoma cells.
Thus, we conclude that miR-378 acts as a potential 
tumor suppressor in GBM, a function that is accomplished 
by target p38. miR-378 could enhance the sensitivity of 
curcumin treatment in U87 cells, which can help us solve 
the toxicity of high-dose curcumin. Collectively, our 
results together with previous reports clearly suggest that 
miR-378 plus curcumin could be a useful combination 
for the treatment of GBM. In the future, studies on the 
regulation of miR-378 promoter may help to identify 
small molecule drugs that may induce the endogenous 
expression of miR-378. An improved understanding of the 
interplay between microRNAs and therapeutic agents will 
allow for improved treatment of GBM.
MATERIALS AND METHODS
Cell lines and culturing conditions
Human glioblastoma U87 cell lines stably 
expressing miR-378 (U87-miR-378) or green fluorescent 
protein as control (U87-GFP) were obtained from Dr. 
Burton Yang [40]. The cell lines were cultured in DMEM 
supplemented with 10% fetal bovine serum (Hyclone, 
Thermo Scientific) at 37°C under humidified atmosphere 
of 5% CO2, 95% air.
Preparation of curcumin-PVP solid dispersion
Curcumin was purchased from Tianjin Guangfu 
Fine Chemical Research Institute (Tianjin, China). 
Ranitidine hydrochloride was purchased from Alpharma 
Pharmaceuticals Inc. (Piscataway, NJ, USA); the PVP 
K30 was purchased from BASF Pharmacy Co. Ltd 
(Ludwigshafen, Germany). The curcumin–PVP solid 
dispersion were prepared as descripted previously [41]. In 
brief, 1:6 mixtures of curcumin-SDS and PVP K30 in were 
produced by conventional solvent evaporation method. 
Curcumin/PVP K30 were dissolved in a minimum volume 
of ethanol and the solvent was removed under vacuum in 
a rotavapor at 65°C and 80 rpm for 8h. The resulted solid 
dispersion was pulverized with mortar and pestle, passed 
through a 250-μm sieve (mesh size 60), kept in vacuum-
desiccator at 40°C for 24h, and then stored in a desiccator 
at room temperature.
Transfection of U87 with miR-378 inhibitor
A total of 2 × 105 cells per well of U87 cells were 
seeded in 6-well plates and transfected with miR-378 
mimic or inhibitor (Ambion, Thermo Scientific, Waltham, 
MA, USA) following Fast-Forward Transfection protocol 
(QIAGEN, Hilden, Germany). 3 days post-transfection, 
the cells were harvested for total RNA isolation or protein 
extraction.
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Animal experiments
All animal work was conducted following the 
guidelines of Public Health Service Policy on Humane 
Care of Laboratory Animals, and approved by the 
Institution Animal Care and Use Committee at the 
MGH. 6-7 weeks old male SCID mice were purchased 
from the Cox-7 animal facility in MGH and used in the 
experiments. To generating tumor xenografts, 2 million 
U87-miR-378 or U87-GFP cells were subcutaneously 
injected into the hind legs of the mice. 7 days post- 
implantation, the mice were randomly divided into 5 
groups PBS, PVP, and curcumin treatment groups with a 
dose of 30 mg/kg, 60 mg/kg, and 120 mg/kg, respectively. 
Each group has 7 or 8 animals and the mice received daily 
gavage (1 time/mouse/day) for 2 weeks. Mouse body 
weight and tumor growth were monitored 2 times/week 
during the 2-week treatment.
MTT cell viability assay
U87-miR-378 or U87-GFP cells were seeded in 96 
well plates at 2000/per well and incubated for 24 hours 
before drug treatment were conducted. When treatments 
were completed, 20 μl of 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) reagent (5 mg/
ml, Sigma-Aldrich) was added to each well and incubated 
at 37°C for 3h. Then the medium was discarded and 150 
μl DMSO (Sigma-Aldrich) was added to each well and 
incubated for 10 min at room temperature. Absorbance 
was measured at a wavelength of 570 nm by SpectraMax 
250 microplate reader (Molecular Devices Corp, Concord, 
ON, Canada).
Apoptosis assay
U87-miR-378 and U87-GFP control cells were 
harvested by trypsinization and washed once with PBS. 
1 X 105 cells were stained with FITC-conjugated annexin 
V and propidium iodide purchased from Phoenix Flow 
Systems (San Diego, CA, USA) following manufacturer's 
instructions. The stained cells were then analyzed on a 
FACSCalibur flow cytometer (BDIS, Becton Dickinson, 
San Jose, CA, USA). Data was analyzed with Cell Quest 
software (BDIS).
Colony formation assay
Single cell suspensions were prepared, counted, 
plated into T25 tissue culture flasks. At each dose point, 
4-6 flasks containing a 2-4 folds range of test cells were 
plated. Cells were routinely plated into medium with G418 
(400 µg/ml, Fisher BioReagents, Fair Lawn, NJ, USA). 
Following treatment, the control cells were cultured for 
8 days. Cells exposed to high doses were cultured up 
to 18 days, stained with crystal violet (Sigma-Aldrich). 
Colonies containing more than 50 cells were counted. The 
results were repeated in three independent experiments. 
The surviving fraction (SF) was calculated as a ratio of the 
number of colonies formed and the product of the number 
of cells plated and the plating efficiency.
Western blot
Proteins of cell lysate were separated on a 10-15% 
SDS-PAGE gel and then transferred onto the Immun-Blot 
PVDF membrane (Biorad). After blocking, the membrane 
was incubated overnight at 4°C with 1: 1000 primary 
antibodies p-P38 (#9211, Cell Signaling), p-AKT (#4060, 
Cell Signaling), p-ERK (#4370, Cell Signaling), Bax 
(#2772, Cell Signaling), PCNA (#2586, Cell Signaling), 
and anti-β-actin antibodies. Neuropilin (#SC554, Santa 
Cruze) antibody was diluted in 1:200 in 5% BSA. After 
washing three times with TBST, the membrane was 
incubated in corresponding secondary antibody (Bio-
Rad, Hercules, CA, USA) at 1: 2000 dilutions for another 
1 hour. Excess antibody was washed away three times 
with TBST and signal was developed with ECL western 
blotting detection system (Amersham Biosciences).
MiRNA analysis
For miRNA analysis, cDNA synthesis and qPCR 
was performed using TaqMan miRNA assays according 
to the manufacturer's recommendations (Applied 
Biosystems). Experimental groups were analyzed in 
replicates of six and normalized to U6.
Statistical analysis
Data are presented as mean ± SD. Comparisons 
among different groups were performed by t-test with 
Primer of Biostatistics. P<0.05 was considered statistically 
significantly.
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